or less distinct AUC/MIC relationships with the antimicrobial effect were established, but the equiefficient AUC/ MIC ratio and equiefficient dose could not be predicted because of the lack of a comparator.
Such predictions may be based on an analysis of bacterial strain-and species-independent AUC/MIC relationships with the intensity of the antimicrobial effect (I E , the area between control growth and bacterial killing/regrowth curves) 9 and the species-specific dose-response relationships as established over a wide range of AUC/MICs. 10, 11 In the present study, experiments that include the complete regrowth phase were used to compare the antimicrobial effects of moxifloxacin and levofloxacin on Staphylococcus aureus, Escherichia coli and Klebsiella pneumoniae in an in vitro dynamic model.
Materials and methods

Antimicrobial agents and bacterial strains
Moxifloxacin and levofloxacin (kindly provided by Bayer Corporation, West Haven, CT, USA and Ortho-McNeill Pharmaceuticals, Raritan, NJ, USA, respectively) were used in the study.
Two clinical isolates of S. aureus with different susceptibilities to moxifloxacin and levofloxacin and one each of E. coli and K. pneumoniae were selected for the study. The true MICs for these organisms determined by multiple serial dilutions as described elsewhere 12 were 0.18 mg/L (S. aureus 944), 0.37 mg/L (S. aureus 916), 0.10 mg/L (E. coli 11557) and 0.32 mg/L (K. pneumoniae 56) of moxifloxacin and 0.25, 0.60, 0.20 and 0.20 mg/L, respectively, of levofloxacin. For the prediction of the antimicrobial effects of these quinolones on hypothetical representatives of the above-mentioned species, weighted geometric means of the reported MIC 50 s of moxifloxacin [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] and levofloxacin 13, 18, 19, 22, 24, [27] [28] [29] [30] were calculated. The respective geometric values of the MIC 50 of moxifloxacin for S. aureus, E. coli and K. pneumoniae were 0.15, 0.03 and 0.06 mg/L, and those of levofloxacin were 0.7, 0.03 and 0.18 mg/L, respectively.
In vitro dynamic model and simulated pharmacokinetic profiles
A dynamic model described previously 31 was used in the study. The operation procedures, reliability of simulations of the quinolone pharmacokinetic profiles and the high reproducibility of the time-kill curves provided by the model have been reported elsewhere.
12
A series of monoexponential profiles that mimic single dose administration of moxifloxacin and levofloxacin were simulated. The simulated half-lives (12.1 h for moxifloxacin and 6.8 h for levofloxacin) represented weighted means of the values reported in humans: 9.1-13.4 h 32,33 and 6.0-7.4 h, [34] [35] [36] [37] [38] respectively. The respective rates of fresh nutrient medium influx into the 60 mL (moxifloxacin) or 40 mL (levofloxacin) central compartments and the antibiotic-and bacteria-containing medium efflux from this compartment were 3.4 and 4.1 mL/h, respectively.
The mean simulated AUC/MIC ratios of moxifloxacin and levofloxacin were similar to those used in our previous studies with trovafloxacin and ciprofloxacin: 10 59, 118, 235 and 470, and 115, 230, 460 and 922, respectively. To provide comparable AUC/MIC ratios of moxifloxacin and levofloxacin, the latter of which has a shorter half-life, its peak concentration/MIC ratios were higher than those of the former quinolone (Figure 1 ). The overall range of the simulated peak concentration/MIC ratios was 3-27 for moxifloxacin and 12-95 for levofloxacin.
Determination of the time-kill curves and the antimicrobial effect
In each experiment multiple sampling of medium containing bacteria from the central compartment was performed throughout the observation period. The duration of the experiments was defined in each case as the time until antibiotic-exposed bacteria reached the maximum numbers observed in the absence of antibiotic (у10 9 cfu/mL). The lower limit of the viable counts was 2 ϫ 10 2 cfu/mL. The procedure used for quantification of viable counts has been reported elsewhere.
12
As described earlier, 31 the antimicrobial effect (E) at each time point (t) was expressed by the difference between logarithms of the respective viable counts in the control growth curve (N C ) and in the time-kill curve (N A ): E(t) ϭ log N C -log N A (Figure 2 ). Either the area between the log N C -t and log N A -t curves (Figure 2a ) or the area under the E-t curve (Figure 2b ) describes the total antimicrobial Figure 1 . In vitro simulated pharmacokinetic profiles of moxifloxacin (bold lines) and levofloxacin (thin lines). Quinolone peak/MIC ratios simulated for moxifloxacin were 3, 7, 13 and 27, and for levofloxacin 12, 24, 48 and 95. effect as expressed by I E . The upper limit of bacterial numbers, i.e. the cutoff level on the regrowth and control growth curves used to determine the I E was 10 11 cfu/mL. In case of lower counts, they were extrapolated to the cutoff level by using a logistic function.
Relationships between the effect and the AUC/MIC or dose
The I E versus log AUC/MIC data sets obtained with each quinolone against S. aureus, E. coli and K. pneumoniae were fitted by the equation I E ϭ a ϩ b log AUC/MIC (Equation 1).
When predicting the AUC/MIC breakpoints for moxifloxacin and levofloxacin, the reported breakpoint value for ciprofloxacin, 125, which correlated with bacterial eradication in patients with respiratory tract infections, 39 was used. This reference breakpoint reflects the critical value of the area under the inhibitory curve (AUIC), which is similar to the AUC/MIC.
To express the antimicrobial effects as a function of quinolone dose (D), the AUC in the linear relationship between I E and log AUC that corresponds to Equation 1 written for a given quinolone-pathogen pair was substituted by D according to the linear equation: AUC ϭ c D (Equation 2). The values of c for moxifloxacin and levofloxacin (0.08 and 0.11, respectively) were calculated on the basis of reported pharmacokinetic data that were obtained with moxifloxacin (Ds from 50 to 800 mg) 32,33 and levofloxacin (Ds from 100 to 1000 mg). 40 Correlation and regression analyses of the relationship between I E and log AUC/MIC for each quinolone were performed at a level of significance of P ϭ 0.05.
Results
The time courses of viable counts that reflect killing and regrowth of S. aureus, E. coli and K. pneumoniae exposed to monoexponentially decreasing concentrations of moxifloxacin and levofloxacin as well as the respective control growth curves are shown in Figure 3a -h. As seen in Figure  3 , the time-kill curves observed with both quinolones against these three bacterial species yielded similar patterns. At the AUC/MIC ratios studied, regrowth followed a rapid and considerable reduction in bacterial numbers. Steep ascending branches of the E-t curves (Figure 3i -p) reflect the rapid onset of the antimicrobial effect. The maximal Es (E max s) produced by both quinolones were greater at higher AUC/MICs, although the AUC/MIC-induced differences of E max s were less pronounced than those of the time shift of the regrowth phase (Figure 3a -h) and of the descending branches of the E-t curves (Figure 3i-p). As seen in Figure 3 , these shifts were distinctly dependent on the simulated AUC/MIC: the higher the AUC/MIC, the later the regrowth or the disappearance of the antimicrobial effect.
The respective I E s correlated well with log AUC/MICs for both moxifloxacin and levofloxacin ( Figure 4 ). The I E -log AUC/MIC plots fitted by Equation 1 were linear, bacterial species and strain independent but quinolone specific (r 2 0.99 in both cases). The effects produced by the same AUC/MIC ratio of moxifloxacin were greater than those of levofloxacin. For example, at AUC/MIC ϭ 250, the I E of moxifloxacin was 45% higher than that of levofloxacin.
Based effect as produced by a 400 mg D 24 of moxifloxacin, would be 10-fold higher (5000 mg) than the usual clinical dose of levofloxacin. Based on the extrapolated relationship between D and AUC of levofloxacin, the 5000 mg D 24 is out of the actual D range in the AUC-D set fitted by Equation 2, and this latter estimate is more conditional than the other values shown in Figure 5 . However, it does reflect the order of difference between the quinolone doses that might be necessary to provide the same antimicrobial effect. The doses of moxifloxacin and levofloxacin necessary to efficiently suppress the growth of E. coli (30 and 36 mg, respectively) and K. pneumoniae (60 and 220 mg, respectively) are much lower than 400 mg of moxifloxacin or 500 mg of levofloxacin.
Discussion
This comparative pharmacodynamic study provides doseresponse relationships and prediction of equiefficient doses of moxifloxacin and levofloxacin for E. coli, K. pneumoniae and S. aureus. These predictions are based on bacterial strain-and species-independent AUC/MIC relationships of the total antimicrobial effect (I E ) for the novel quinolone (moxifloxacin) and the comparator (levofloxacin) (r 2 0.99 in both cases).
Previously reported AUC/MIC relationships using alternative integral endpoints of moxifloxacin's effect were either weaker (r 2 0.51-0.69 with a linear model 8 and r The usefulness of long-term observations that include the entire regrowth phase rather than only initial bacterial killing in establishing AUC/MIC-response relationships has been demonstrated with trovafloxacin and ciprofloxacin. 10, 11, 31 In this light, the lack of reported correlations between the AUC/MIC ratio of levofloxacin and ciprofloxacin and the time to a 1000-fold reduction in starting inoculum (T 99.9% ) in experiments with Streptococcus pneumoniae 41 and between doses of several quinolones and T 99.9% with S. aureus 42 might be expected. Similarly, minimal, if any, dose-induced changes could be seen in the rate and extent of initial killing of S. pneumoniae and Enterococcus faecalis exposed to moxifloxacin.
2 In another study, although initial killing of K. pneumoniae was similar with moxifloxacin and trovafloxacin, the patterns of bacterial regrowth were quite different. 5 Thus, the establishment of AUC/MIC-response relationships may depend dramatically on the experimental design and the method of quantification of the antimicrobial effect.
The I E -log AUC/MIC relationships established here for moxifloxacin and levofloxacin revealed greater antimicrobial effects with moxifloxacin at a given AUC/MIC ratio. Similar differences were reported in our studies with trovafloxacin and ciprofloxacin.
10,11 By comparing the I E -log AUC/MIC relationships for moxifloxacin and levofloxacin with that for ciprofloxacin, 10 AUC/MIC breakpoints can be predicted that might be equivalent to Schentag's AUC/ MIC ϭ 125 established in a clinical setting. 39 As seen in Figure 4b , to provide an 'acceptable' I E ϭ 200 (log cfu/mL)•h that corresponds to the AUC/MIC ϭ 125 for ciprofloxacin, the equivalent AUC/MIC breakpoint for moxifloxacin might be lower, at 80, and that for levofloxacin might be higher, at 130, than the breakpoint value for ciprofloxacin. As follows from Equation 2, a single dose of moxifloxacin (400 mg) provides its AUC of 33 mg•h/L. Its MIC breakpoint is equal to 33/80 ϭ 0.41 mg/L. The respective value for a 500 mg dose of levofloxacin is lower: 46.5/130 ϭ 0.35 mg/L. These MIC breakpoints are higher than the geometric means of MIC 50 s of moxifloxacin and levofloxacin for E. coli (0.03 mg/L for both agents) and K. pneumoniae (0.06 and 0.18 mg/L, respectively). Most strains of S. aureus will not be covered by levofloxacin (geometric mean of MIC 50 s 0.7 mg/L) whereas they are more likely to be covered by moxifloxacin (geometric mean of MIC 50 s 0.15 mg/L).
Although the relevance of these estimates may be verified only in a clinical setting, together with the equiefficient doses, they might be useful for in vitro comparison of relative efficacies of the quinolones. In particular, these data support the important role of the longer half-lives of the newer extended spectrum quinolones whose pharmacokinetic profiles result in a greater antimicrobial effect. 
